| Fumena (vorolanib) / Tyrogenex, Betta Pharma |
NCT01296581: Safety Study of X-82 in Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 52 | US | X-82 | Tyrogenex | Advanced Solid Tumors | 01/14 | 01/17 | | |
|
NCT01863485: Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China |
|
|
| Completed | 1 | 44 | RoW | CM082 Tablet, X-82 | AnewPharma, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Cancer | 10/14 | 05/16 | | |
ChiCTR-IID-17013889: Phase I clinical trial of the safety, tolerability, pharmacokinetics and initial efficacy of CM082 in the treatment of wet age-related macular degeneration (wAMD) |
|
|
| Completed | 1 | 108 | | 25mg dose ;50mg dose ;75mg dose ;100mg dose | Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University, Kananji Medical Technology (Shanghai) Co., Ltd. | wet age-related macular degeneration | | | | |
NCT02146222: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors |
|
|
| Completed | 1 | 14 | US | VEGFR/PDGFR dual kinase inhibitor X-82, X-82, docetaxel, RP 56976, Taxotere, TXT, fluorine F 18 fluorothymidine, 18F-FLT, 3'-deoxy-3'-[18F]fluorothymidine, fluorothymidine F-18, positron emission tomography/computed tomography, pharmacological study, pharmacological studies, laboratory biomarker analysis | University of Wisconsin, Madison, Tyrogenex | Unspecified Adult Solid Tumor, Protocol Specific | 12/16 | 12/16 | | |
NCT02577458: Study of the Combination of CM082 With Everolimus in Patients With mRCC |
|
|
| Unknown status | 1 | 18 | RoW | CM082, X-82, Everolimus, Affinitor | AnewPharma, Peking University Cancer Hospital & Institute | Renal Cell Carcinoma Recurrent | 03/18 | 06/18 | | |
NCT03286244: Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer |
|
|
| Unknown status | 1 | 21 | RoW | CM082 plus paclitaxel | AnewPharma | Advanced Gastric Cancer | 08/19 | 08/20 | | |
NCT03511222: Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors |
|
|
| Terminated | 1 | 16 | US | Vorolanib, X-82, Nivolumab, Opdivo, Pembrolizumab, Keytruda | Washington University School of Medicine, Xcovery Holding Company, LLC | Solid Tumor, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 08/19 | 05/20 | | |
NCT04126668: A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers |
|
|
| Completed | 1 | 24 | RoW | CM082 with fed or fasting | AnewPharma | Advanced Malignant Solid Tumors | 01/20 | 01/20 | | |
| Suspended | 1 | 56 | RoW | CM082 tablet, X-82 | AnewPharma, West China Hospital | Age-Related Macular Degeneration | 06/20 | 06/20 | | |
NCT04328506: Bioequivalency Study of CM082 Tablet in Healthy Volunteers |
|
|
| Completed | 1 | 96 | RoW | CM082 tablet (test product), CM082 tablet (reference product) | AnewPharma | Advanced Malignant Solid Tumors | 07/20 | 07/20 | | |
NCT04434326: The Absorption, Metabolism and Excretion of [14C]CM082 in Human |
|
|
| Completed | 1 | 4 | RoW | [14]CM082 suspension | AnewPharma | Advanced Solid Tumor | 10/21 | 10/21 | | |
NCT04222842: CM082 in Patients With Myopic Choroidal Neovascularization (CNV) |
|
|
| Suspended | 1 | 96 | RoW | CM082, X-82 | AnewPharma | Myopic Choroidal Neovascularisation | 12/21 | 12/21 | | |
NCT03792958: Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 19 | RoW | CM082, X-82 | AnewPharma, Shanghai East Hospital | Advanced Malignant Solid Tumors | 06/23 | 06/23 | | |
